Standard
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. / Olesen, Uffe Høgh; Petersen, Jakob Gramstrup; Garten, Antje; Kiess, Wieland; Yoshino, Jun; Imai, Shin-Ichiro; Christensen, Mette Knak; Fristrup, Peter; Thougaard, Annemette Vinding; Björkling, Fredrik; Jensen, Peter Buhl; Nielsen, Søren Jensby; Sehested, Maxwell.
I:
BMC Cancer, Bind 10, 10.12.2010, s. 677.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Olesen, UH, Petersen, JG, Garten, A, Kiess, W, Yoshino, J, Imai, S-I, Christensen, MK, Fristrup, P, Thougaard, AV
, Björkling, F, Jensen, PB, Nielsen, SJ & Sehested, M 2010, '
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase',
BMC Cancer, bind 10, s. 677.
https://doi.org/10.1186/1471-2407-10-677
APA
Olesen, U. H., Petersen, J. G., Garten, A., Kiess, W., Yoshino, J., Imai, S-I., Christensen, M. K., Fristrup, P., Thougaard, A. V.
, Björkling, F., Jensen, P. B., Nielsen, S. J., & Sehested, M. (2010).
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
BMC Cancer,
10, 677.
https://doi.org/10.1186/1471-2407-10-677
Vancouver
Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S-I o.a.
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
BMC Cancer. 2010 dec. 10;10:677.
https://doi.org/10.1186/1471-2407-10-677
Author
Olesen, Uffe Høgh ; Petersen, Jakob Gramstrup ; Garten, Antje ; Kiess, Wieland ; Yoshino, Jun ; Imai, Shin-Ichiro ; Christensen, Mette Knak ; Fristrup, Peter ; Thougaard, Annemette Vinding ; Björkling, Fredrik ; Jensen, Peter Buhl ; Nielsen, Søren Jensby ; Sehested, Maxwell. / Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. I: BMC Cancer. 2010 ; Bind 10. s. 677.
Bibtex
@article{508a791fb1a24346bfbedea6a2f83a9a,
title = "Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase",
abstract = "Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.",
keywords = "Faculty of Health and Medical Sciences",
author = "Olesen, {Uffe H{\o}gh} and Petersen, {Jakob Gramstrup} and Antje Garten and Wieland Kiess and Jun Yoshino and Shin-Ichiro Imai and Christensen, {Mette Knak} and Peter Fristrup and Thougaard, {Annemette Vinding} and Fredrik Bj{\"o}rkling and Jensen, {Peter Buhl} and Nielsen, {S{\o}ren Jensby} and Maxwell Sehested",
year = "2010",
month = dec,
day = "10",
doi = "10.1186/1471-2407-10-677",
language = "English",
volume = "10",
pages = "677",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
}
RIS
TY - JOUR
T1 - Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
AU - Olesen, Uffe Høgh
AU - Petersen, Jakob Gramstrup
AU - Garten, Antje
AU - Kiess, Wieland
AU - Yoshino, Jun
AU - Imai, Shin-Ichiro
AU - Christensen, Mette Knak
AU - Fristrup, Peter
AU - Thougaard, Annemette Vinding
AU - Björkling, Fredrik
AU - Jensen, Peter Buhl
AU - Nielsen, Søren Jensby
AU - Sehested, Maxwell
PY - 2010/12/10
Y1 - 2010/12/10
N2 - Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
AB - Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
KW - Faculty of Health and Medical Sciences
U2 - 10.1186/1471-2407-10-677
DO - 10.1186/1471-2407-10-677
M3 - Journal article
C2 - 21144000
VL - 10
SP - 677
JO - B M C Cancer
JF - B M C Cancer
SN - 1471-2407
ER -